Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
FX Lescure, H Honda, RA Fowler, JS Lazar… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised …
…, D Lebeaux, B Lefevre, S Leroy, FX Lescure… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …
[HTML][HTML] Compassionate use of remdesivir for patients with severe Covid-19
…, T Feldt, G Green, ML Green, FX Lescure… - … England Journal of …, 2020 - Mass Medical Soc
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases,
has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a …
has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a …
Type 1 interferons as a potential treatment against COVID-19
Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a
clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the …
clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the …
[HTML][HTML] First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020
…, S Ismael, D Nguyen, D Malvy, FX Lescure… - …, 2020 - eurosurveillance.org
A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) causing
a cluster of respiratory infections (coronavirus disease 2019, COVID-19) in Wuhan, China, …
a cluster of respiratory infections (coronavirus disease 2019, COVID-19) in Wuhan, China, …
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
…, E Fois, R Lepeule, TA Szwebel, FX Lescure… - Bmj, 2020 - bmj.com
Objective To assess the effectiveness of hydroxychloroquine in patients admitted to hospital
with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design …
with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design …
Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?
…, D Slama, C Joseph, A Lemaignen, FX Lescure… - Journal of Infection, 2020 - Elsevier
For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing
non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID…
non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID…
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
…, B Montes, K Bouiller, FX Lescure… - Proceedings of the …, 2021 - National Acad Sciences
The characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …
[HTML][HTML] Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study
…, C Choquet, D Descamps, J Ghosn, FX Lescure… - Clinical Microbiology …, 2023 - Elsevier
Objectives A global outbreak of monkeypox virus infections in human beings has been
described since April 2022. The objectives of this study were to describe the clinical …
described since April 2022. The objectives of this study were to describe the clinical …
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection
…, MP Debray, M Gilbert, FX Lescure… - European …, 2020 - Eur Respiratory Soc
We read with great interest the series of cases reported by Mo et al. [1], describing pulmonary
function after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in …
function after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in …